{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT03628677",
      "orgStudyIdInfo": {
        "id": "AB154CSP0001"
      },
      "organization": {
        "fullName": "Arcus Biosciences, Inc.",
        "class": "INDUSTRY"
      },
      "briefTitle": "A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies",
      "officialTitle": "A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies"
    },
    "statusModule": {
      "statusVerifiedDate": "2024-05",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2018-09-12",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2025-01-23",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2025-01-23",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2018-07-26",
      "studyFirstSubmitQcDate": "2018-08-10",
      "studyFirstPostDateStruct": {
        "date": "2018-08-14",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2025-02-03",
      "lastUpdatePostDateStruct": {
        "date": "2025-02-04",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Arcus Biosciences, Inc.",
        "class": "INDUSTRY"
      },
      "collaborators": [
        {
          "name": "Gilead Sciences",
          "class": "INDUSTRY"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab (AB154) as monotherapy and in combination with zimberelimab (AB122) in participants with advanced solid malignancies."
    },
    "conditionsModule": {
      "conditions": [
        "Solid Tumor, Unspecified, Adult"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "NON_RANDOMIZED",
        "interventionModel": "SEQUENTIAL",
        "interventionModelDescription": "Dose Escalation Design",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 75,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Domvanalimab Monotherapy",
          "type": "EXPERIMENTAL",
          "description": "Varying Doses of domvanalimab Monotherapy",
          "interventionNames": [
            "Drug: Domvanalimab"
          ]
        },
        {
          "label": "Domvanalimab + zimberelimab Q2W Combination Therapy",
          "type": "EXPERIMENTAL",
          "description": "Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab",
          "interventionNames": [
            "Drug: Domvanalimab",
            "Drug: Zimberelimab"
          ]
        },
        {
          "label": "Domvanalimab + zimberelimab Q3W Combination Therapy",
          "type": "EXPERIMENTAL",
          "description": "Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab",
          "interventionNames": [
            "Drug: Domvanalimab",
            "Drug: Zimberelimab"
          ]
        },
        {
          "label": "Domvanalimab + zimberelimab Q4W Combination Therapy",
          "type": "EXPERIMENTAL",
          "description": "Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab",
          "interventionNames": [
            "Drug: Domvanalimab",
            "Drug: Zimberelimab"
          ]
        },
        {
          "label": "Domvanalimab and Zimberelimab Q6W combination therapy",
          "type": "EXPERIMENTAL",
          "description": "Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab",
          "interventionNames": [
            "Drug: Domvanalimab",
            "Drug: Zimberelimab"
          ]
        },
        {
          "label": "Fixed dose Domvanalimab Q3W or Q4W and Zimberelimab Q3W, Q4W",
          "type": "EXPERIMENTAL",
          "description": "Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab",
          "interventionNames": [
            "Drug: Domvanalimab",
            "Drug: Zimberelimab"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Domvanalimab",
          "description": "Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT",
          "armGroupLabels": [
            "Domvanalimab + zimberelimab Q2W Combination Therapy",
            "Domvanalimab + zimberelimab Q3W Combination Therapy",
            "Domvanalimab + zimberelimab Q4W Combination Therapy",
            "Domvanalimab Monotherapy",
            "Domvanalimab and Zimberelimab Q6W combination therapy",
            "Fixed dose Domvanalimab Q3W or Q4W and Zimberelimab Q3W, Q4W"
          ],
          "otherNames": [
            "AB154"
          ]
        },
        {
          "type": "DRUG",
          "name": "Zimberelimab",
          "description": "Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1",
          "armGroupLabels": [
            "Domvanalimab + zimberelimab Q2W Combination Therapy",
            "Domvanalimab + zimberelimab Q3W Combination Therapy",
            "Domvanalimab + zimberelimab Q4W Combination Therapy",
            "Domvanalimab and Zimberelimab Q6W combination therapy",
            "Fixed dose Domvanalimab Q3W or Q4W and Zimberelimab Q3W, Q4W"
          ],
          "otherNames": [
            "AB122"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Number of Participants with Treatment Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0",
          "description": "Number of Participants Treated with domvanalimab or domvanalimab in Combination with zimberelimab with Treatment Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0",
          "timeFrame": "From First Dose Date to 100 Days After Last Dose"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "AB154 Peak Plasma Concentration (Cmax)",
          "description": "Peak Plasma Concentration (Cmax) of domvanalimab",
          "timeFrame": "Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks"
        },
        {
          "measure": "Zimberelimab Peak Plasma Concentration (Cmax)",
          "description": "Peak Plasma Concentration (Cmax) of zimberelimab",
          "timeFrame": "Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks"
        },
        {
          "measure": "Domvanalimab Time of Peak Concentration (Tmax)",
          "description": "Time of Peak Concentration (Tmax) of domvanalimab",
          "timeFrame": "Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks"
        },
        {
          "measure": "Zimberelimab Time of Peak Concentration (Tmax)",
          "description": "Time of Peak Concentration (Tmax) of zimberelimab",
          "timeFrame": "Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks"
        },
        {
          "measure": "Domvanalimab Area Under the Plasma Concentration Versus Time Curve (AUC)",
          "description": "Area Under the Plasma Concentration Versus Time Curve (AUC) of domvanalimab",
          "timeFrame": "Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks"
        },
        {
          "measure": "Zimberelimab Area Under the Plasma Concentration Versus Time Curve (AUC)",
          "description": "Area Under the Plasma Concentration Versus Time Curve (AUC) of zimberelimab",
          "timeFrame": "Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks"
        },
        {
          "measure": "Immunogenicity Indicators: Anti-Drug Antibodies (ADA)",
          "description": "Number of Participants who Develop Antidrug Antibodies to AB154 and/or AB122",
          "timeFrame": "Day 1, Day 15, Day 29, Day 43, Day 57, Day 85 and 30 Days After Last Dose, up to 52 weeks"
        },
        {
          "measure": "Overall Response Rate",
          "description": "Number of Participants with Complete or Partial Response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v.1.1",
          "timeFrame": "First Dose Date to Progression or Last Tumor Assessment, up to 1 year"
        },
        {
          "measure": "Duration of Response",
          "description": "Time at Which Response Criteria are Met for Complete Response or Partial Response (Whichever Occurs First) Until the First Date of Recurrence, Progression or Death per RECIST v1.1",
          "timeFrame": "Start Date of Response to First Progression/Death, up to 1 year"
        },
        {
          "measure": "Disease Control Rate",
          "description": "Number of Participants with Complete Response, Partial Response, or Stable Disease for Greater Than 6 Months per RECIST v1.1",
          "timeFrame": "First Dose Date to First Progression/Death, up to 1 year"
        },
        {
          "measure": "Progression Free Survival",
          "description": "Number of Participants Without Disease Progression per RECIST v1.1",
          "timeFrame": "First Dose Date to First Progression/Death, up to 1 year"
        },
        {
          "measure": "Overall Survival",
          "description": "Overall Survival Rate, Defined as Time Between First Dose Date and Date of Death",
          "timeFrame": "First Dose Date to Date of Death, up to 1 year"
        }
      ],
      "otherOutcomes": [
        {
          "measure": "Domvanalimab Receptor Occupancy",
          "description": "Receptor Occupancy May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples",
          "timeFrame": "Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks"
        },
        {
          "measure": "Domvanalimab Immunophenotyping",
          "description": "Immunophenotyping May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples",
          "timeFrame": "Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks"
        },
        {
          "measure": "Domvanalimab Gene Expression",
          "description": "Gene Expression May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples",
          "timeFrame": "Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks"
        },
        {
          "measure": "Domvanalimab Cytokines",
          "description": "Cytokines May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples.",
          "timeFrame": "Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks"
        },
        {
          "measure": ".Zimberelimab Receptor Occupancy",
          "description": "Receptor Occupancy May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples",
          "timeFrame": "Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks"
        },
        {
          "measure": "Zimberelimab Immunophenotyping",
          "description": "Immunophenotyping May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples",
          "timeFrame": "Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks"
        },
        {
          "measure": "Zimberelimab Cytokines",
          "description": "Cytokines May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples",
          "timeFrame": ": Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks"
        },
        {
          "measure": "Zimberelimab Gene Expression",
          "description": "Gene Expression May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples",
          "timeFrame": "Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141, and 30 Days After Last Dose, up to 52 weeks"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Capable of giving signed informed consent\n* Male or female participants ≥ 18 years of age at the time of screening\n* Negative serum pregnancy test at screening and prior to dosing on Cycle 1 Day 1; negative serum or urine pregnancy test on the first day of each subsequent treatment period\n* Participants with any pathologically confirmed solid tumor type for which no standard of care therapy exists\n* Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The measurable lesion must be outside of a radiation field if the participant received prior radiation\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 7. Confirmation that an archival tissue sample is available and ≤ 6 months old; if not, a new biopsy of a tumor must be obtained 8. Immunosuppressive doses of systemic medications, such as corticosteroids or absorbed topical corticosteroids (doses \\> 10 mg/day prednisone or equivalent) must be discontinued at least 2 weeks (14 days) before investigational product administration. Physiologic doses of corticosteroids ≤ 10 mg/day of prednisone or its equivalent may be permitted\n* Prior surgery that required general anesthesia or other major surgery as defined by the Investigator must be completed at least 4 weeks before investigational product administration\n* Negative tests for hepatitis B surface antigen, hepatitis C virus antibody (or hepatitis C qualitative ribonucleic acid \\[RNA; qualitative\\]), and human immunodeficiency virus (HIV)-1 and HIV-2 antibody at screening\n* Adequate organ and marrow function\n\nExclusion Criteria:\n\n* Use of any live vaccines against infectious diseases (eg, influenza, varicella) within 4 weeks (28 days) of initiation of investigational product\n* Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of investigational product hazardous (eg, interstitial lung disease, active infections requiring antibiotics, recent hospitalization with unresolved symptoms)\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the pre-screening or screening visit through 120 days after the last dose of domvanalimab as monotherapy and in combination with zimberelimab.\n* Participants who require a Legally Authorized Representative (LAR) to provide informed consent on their behalf.\n* Any active autoimmune disease or a documented history of autoimmune disease or history of a syndrome that required systemic steroids or immunosuppressive medications, except for vitiligo or resolved childhood asthma/atopy. Participants with asthma who require intermittent use of bronchodilators (such as albuterol) will not be excluded from this study\n* Prior malignancy active within the previous year except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer\n* Has had prior chemotherapy, targeted small-molecule therapy, immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer), biologic agents or radiation therapy within 4 weeks (or 5 half-lives) prior to Day 1 or has not recovered from AEs due to a previously administered agent\n* Use of other investigational drugs within 28 days or at least 5 half-lives before investigational product administration.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Medical Director",
          "affiliation": "Arcus Biosciences, Inc.",
          "role": "STUDY_DIRECTOR"
        }
      ],
      "locations": [
        {
          "facility": "The Angeles Clinic and Research Institute",
          "city": "Los Angeles",
          "state": "California",
          "zip": "90025",
          "country": "United States",
          "geoPoint": {
            "lat": 34.05223,
            "lon": -118.24368
          }
        },
        {
          "facility": "Affinity Health-Hope and Healing Cancer Services, LLC",
          "city": "Hinsdale",
          "state": "Illinois",
          "zip": "60521",
          "country": "United States",
          "geoPoint": {
            "lat": 41.80086,
            "lon": -87.93701
          }
        },
        {
          "facility": "Carolina BioOncology Institute",
          "city": "Huntersville",
          "state": "North Carolina",
          "zip": "28078",
          "country": "United States",
          "geoPoint": {
            "lat": 35.41069,
            "lon": -80.84285
          }
        },
        {
          "facility": "MD Anderson Cancer Center",
          "city": "Houston",
          "state": "Texas",
          "zip": "77030",
          "country": "United States",
          "geoPoint": {
            "lat": 29.76328,
            "lon": -95.36327
          }
        },
        {
          "facility": "START",
          "city": "San Antonio",
          "state": "Texas",
          "zip": "78229",
          "country": "United States",
          "geoPoint": {
            "lat": 29.42412,
            "lon": -98.49363
          }
        },
        {
          "facility": "Medical Oncology Associates, PS (dba Summit Cancer Centers)",
          "city": "Spokane",
          "state": "Washington",
          "zip": "99208",
          "country": "United States",
          "geoPoint": {
            "lat": 47.65966,
            "lon": -117.42908
          }
        },
        {
          "facility": "The Kinghorn Cancer Centre - St Vincent Public Hospital",
          "city": "Darlinghurst",
          "state": "New South Wales",
          "zip": "2010",
          "country": "Australia",
          "geoPoint": {
            "lat": -33.87939,
            "lon": 151.21925
          }
        },
        {
          "facility": "Tweed Hospital",
          "city": "Tweed Heads",
          "state": "New South Wales",
          "zip": "2486",
          "country": "Australia",
          "geoPoint": {
            "lat": -28.17671,
            "lon": 153.5452
          }
        },
        {
          "facility": "Icon Cancer Care Brisbane",
          "city": "South Brisbane",
          "state": "Queensland",
          "zip": "4101",
          "country": "Australia",
          "geoPoint": {
            "lat": -27.48034,
            "lon": 153.02049
          }
        },
        {
          "facility": "Olivia Newton-John Cancer Research Institute-Austin Hostipal",
          "city": "Heidelberg",
          "state": "Victoria",
          "zip": "3084",
          "country": "Australia",
          "geoPoint": {
            "lat": -37.75,
            "lon": 145.06667
          }
        }
      ]
    },
    "referencesModule": {
      "seeAlsoLinks": [
        {
          "label": "AB154CSP0001 - Public Website",
          "url": "https://trials.arcusbio.com/study/?id=AB154CSP0001"
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "YES",
      "description": "Arcus will provide access to individual de-identified participant data and related study documents \\[e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)\\] upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.\n\nFor more information, please visit our website.",
      "infoTypes": [
        "STUDY_PROTOCOL",
        "SAP",
        "CSR"
      ],
      "url": "https://trials.arcusbio.com/our-transparency-policy"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-09"
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C000719848",
          "term": "zimberelimab"
        }
      ]
    }
  },
  "hasResults": false
}